替诺福韦酯与拉米夫定在老年慢性乙型肝炎患者中的疗效比较  

Comparison of efficacy between tenofovir disoproxil and lamivudine for elderly patients with chronic hepatitis B

作　　者：张晓旭[1] 娄宪芝[1] ZHANG Xiao-xu;LOU Xian-zhi(Department of Infectious Diseases,Shenyang Medical College Affiliated Central Hospital,Shenyang 110024,China)

机构地区：[1]沈阳医学院附属中心医院感染科,辽宁省沈阳市110024

出　　处：《广西医学》2018年第20期2411-2413,共3页Guangxi Medical Journal

摘　　要：目的比较替诺福韦酯与拉米夫定在老年慢性乙型肝炎患者中的疗效。方法将75例慢性乙型肝炎老年患者随机分为观察组40例与对照组35例。观察组给予富马酸替诺福韦二吡呋酯片口服,对照组给予拉米夫定口服,两组均治疗48周。比较两组患者治疗前、治疗4周、12周、24周和48周ALT及HBV-DNA水平,以及治疗48周后的ALT复常率和HBV-DNA转阴率。结果观察组ALT及HBV-DNA水平随治疗时间延长而下降的趋势较对照组更明显(均P <0. 05)。治疗48周后,观察组ALT复常率与HBV-DNA转阴率均高于对照组(均P <0. 05)。结论相比于拉米夫定,替诺福韦酯能更有效地降低老年慢性乙型肝炎患者ALT及HBV-DNA水平,提高ALT复常率和HBV-DNA转阴率。Objective To compare the efficacy of tenofovir disoproxil and lamivudine for elderly patients with chronic hepatitis B. Methods Seventy-five elderly patients with chronic hepatitis B were randomly divided into observation group（40 cases） and control group（35 cases）.The observation group was given Tenofovir Disoproxil Fumarate Tablets orally,while the control group was given lamivudine orally .Both groups were treated for 48 weeks.The ALT and HBV-DNA levels before treatment,4,12,24 and 48 weeks after treatment were compared between the two groups,and the normalization rate of ALT and the seroconversion rate of HBV-DNA after 48 weeks of treatment were compared between the two groups as well. Results The ALT and HBV-DNA levels in the observation group showed a more significant tendency to decease with time compared to the controls（all P 〈0.05）.After 48 weeks of treatment,the normalization rate of ALT and the seroconversion rate of HBV-DNA in the observation group were higher than those in the control group（all P 〈0.05）. Conclusion Compared with lamivudine,tenofovir disoproxil can effectively reduce the levels of ALT and HBV-DNA in the elderly patients with chronic hepatitis B,and increase the normalization rate of ALT as well as the seroconversion rate of HBV-DNA.

关 键 词：慢性乙型肝炎 替诺福韦酯 拉米夫定 老年人 临床疗效 

分 类 号：R512.62[医药卫生—内科学]